Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 3.6%

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) fell 3.6% during mid-day trading on Monday . The company traded as low as $41.10 and last traded at $41.10. 193,592 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 809,629 shares. The stock had previously closed at $42.65.

Analysts Set New Price Targets

A number of research analysts recently commented on AGIO shares. JPMorgan Chase & Co. restated a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 3rd. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a report on Tuesday, June 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average price target of $50.67.

Agios Pharmaceuticals Stock Performance

The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -6.88 and a beta of 0.79. The company’s 50 day simple moving average is $39.73 and its 200 day simple moving average is $31.64.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. The business had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The business’s revenue for the quarter was up 46.0% on a year-over-year basis. During the same quarter last year, the business earned ($1.47) earnings per share. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -2.68 EPS for the current year.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Quest Partners LLC bought a new stake in Agios Pharmaceuticals in the fourth quarter worth about $41,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Agios Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 5,040 shares in the last quarter. NEOS Investment Management LLC acquired a new stake in Agios Pharmaceuticals during the fourth quarter valued at approximately $210,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 942 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its holdings in Agios Pharmaceuticals by 31.8% during the fourth quarter. Handelsbanken Fonder AB now owns 12,023 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 2,900 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.